Search

Meibomian gland dysfunction is a chronic and diffuse disease of the meibomian glands, characterized by obstruction and(or)abnormal secretion of the terminal ducts. Clinically, it can lead to tear film abnormalities and inflammation of the ocular surface, resulting in symptoms of ocular irritation and potential corneal damage that may impact visual function. Meibomian gland dysfunction can be classified into two types based on meibomian gland secretion: low secretion type and high secretion type. The low secretion type further includes acinar atrophy type and obstruction type. In recent years, research has revealed that patients with diabetes experience chronic damage to their meibomian gland tissue in the early stages of the disease, leading to structural and functional changes. The incidence and severity of meibomian gland dysfunction are higher in diabetic patients. However, there are numerous complex factors contributing to this condition in diabetes patients, and mechanisms remain unclear at present. This article reviews both domestic and international research progress on the pathological mechanism underlying meibomian gland dysfunction in diabetes.

Rapidly increasing intraocular pressure(IOP)is a typical manifestation of acute angle-closure glaucoma and an important cause of ocular tissue damage, vision loss and even blindness in glaucoma patients. The sharp increase of intraocular pressure in a short period of time in acute angle-closure glaucoma will cause characteristic damage to the structure and function of retina, choroid and optic nerve. Currently, the diagnosis and evaluation of the course of glaucoma is largely dependent on the state of high IOP, changes in the optic nerve and visual field damage, but irreversible damage to the fundus has already been made in glaucoma patients by this time. The microstructural changes in the posterior segment of the eye are more sensitive to high IOP and often appear before optic nerve and visual field damage, which can indicate the damage of high IOP to the eye earlier. Through the evaluation of the imaging characteristics of the posterior segment of the eye, the morphological characteristics that affect the prognosis of glaucoma can be explored, which is clinically important for the early diagnosis of glaucoma.

Retinopathy of prematurity(ROP), an abnormal vascular proliferative retinopathy of prematurity, is a serious condition that can lead to retinal detachment or blindness. With the development of neonatal medicine, the survival rate of low birth weight and low gestational age infants has been increasing, as well as the incidence of ROP. Therefore, studying ROP's pathogenesis and influencing factors is of great clinical importance. Numerous studies have been conducted on the risk factors for ROP, including gestational age, oxygen intake, mode of delivery, neonatal bronchopulmonary dysplasia, and the use of surfactants. At present, it is widely accepted both at home and abroad that preterm birth, low birth weight, and high oxygen concentration after birth are independent risk factors for ROP. In recent years, more and more scholars have found that abnormalities in blood indicators in preterm infants may be associated with the development of ROP. This article reviews the effects of platelets, haemoglobin, blood glucose, inflammatory cells, and lipids on ROP, providing a reference for identifying and preventing risk factors for ROP.

Rubus suavissimus is mainly distributed in Guilin, Liuzhou, Wuzhou and other regions in Guangxi Zhuang Autonomous Region, so it is called as “Guangxi tiancha” in China. R. suavissimus, together with Siraitia grosvenorii and Stevia rebaudianastevia are praised as three famous sweet plants in Guangxi Zhuang Autonomous Region. Zhuang and Yao people use the leaves of R. suavissimus as a tea to treat diabetes, and it is known as the “divine tea” of Yao medicine. Therefore, R. suavissimus is a combination of sugar, tea and medicine, which has great potential for the development of food and medicine. In order to investigate the secondary metabolites with α-glucosidase inhibitory activity from R. suavissimus, herein, the extraction, separation and purification of secondary metabolites were performed on the leaves of R. suavissimus. The structures of purified compounds were determined based on the data of mass spectrometry (HR-ESI-MS) and nuclear magnetic resonance (1H NMR and 13C NMR). In addition, the α-glucosidase inhibitory activity of the purified compounds were evaluated by pharmacological methods simultaneously. The results were as follows: (1) Ten compounds were purified and their structures were elucidated as rubusoside (1), kaempferol 3-O-robinobioside (2), gallic acid (3), dihydrodehydroconiferyl alcohol (4), 5-methoxydihydrodehydroconiferyl alcohol (5), brevifolincarboxylic acid (6), steviolmonoside (7), steviol (8), 16α, 17-dihydroxykaurane (9), and quercetin 3-O-β-D-galactopyranoside (10). Among them, compounds 2, 4, 5 and 9 were isolated from R. suavissimus for the first time. (2) Compounds 2, 3, 5, 6 and 10 showed strong inhibitory activity on α-glucosidase. The IC50 values of compounds 2, 3, 5, 6 and 10 were (0.14 ± 0.03) mg·mL-1, (0.36 ± 0.02) mg·mL-1, (0.44 ± 0.01) mg·mL-1, (0.53 ± 0.04) mg·mL-1 and (0.14 ± 0.03) mg·mL-1 respectively, which were stronger than the positive control acarbose with the IC50 values as (0.69 ± 0.02) mg·mL-1. Thus, compounds 2, 3, 5, 6 and 10, which were isolated from the leaves of R. suavissimus, could be a potential α-glucosidase inhibitors based on their bioactivity results. Compounds with α-glucosidase inhibitory activity from R. suavissimus will provide the basis for development of related hypoglycemic products.